Clinical evaluation of oxprenolol in angina pectoris.

A controlled double-blind clinical evaluation of oxprenolol, a new beta-adrenergic blocking drug, has been carried out in I3 patients with angina pectoris. Objective assessment was based on exercise on a treadmill with continuous radiocardiographic monitoring. The dose of oxprenolol was 8o mg three times a day. There was a significant reduction of the degree of ischaemic ST depression during exercise after oxprenolol treatment, though the amount of exercise was unchanged. It is possible that larger doses of oxprenolol may be of more value in improving exercise tolerance, as well as myocardial ischaemia.

[1]  J. Stuart,et al.  Haemolytic-Uraemic Syndrome with Pericarditis and Pleurisy , 1973 .

[2]  S. Taylor,et al.  Comparison of Adrenergic Beta-blocking Drugs in Angina Pectoris , 1971, British medical journal.

[3]  P. Gillam,et al.  Assessment of propranolol in angina pectoris. Clinical dose response curve and effect on electrocardiogram at rest and on exercise. , 1971, British heart journal.

[4]  S. Behrman.  Ophthalmoscope as viscosimeter. , 1971, British medical journal.

[5]  J. Bensaid,et al.  Long-term clinical results of oxprenolol in the treatment of cardiac arrhythmias, angina pectoris and hypertrophic subaortic stenosis. , 1970, Postgraduate medical journal.

[6]  B. Prichard,et al.  The action of intravenous oxprenolol, practolol, propranolol and sotalol on acute exercise tolerance in angina pectoris: the effect on heart rate and the electrocardiogram. , 1970, Postgraduate medical journal.

[7]  G. Sandler,et al.  Clinical Evaluation of Practolol, a New Cardioselective Beta-blocking Agent in Angina Pectoris , 1970, British medical journal.

[8]  G. Sandler,et al.  Clinical Evaluation of Verapamil in Angina Pectoris , 1968, British medical journal.

[9]  H. Waal.  Hypotensive, antiarrhythmic and chronotropic action of Trasicor (Ciba 39089--Ba). , 1968, The New Zealand medical journal.

[10]  J. Rivier,et al.  Cardio-circulatory effects of beta-adrenergic blockade in organic heart disease. Comparison between propranolol and CIBA 39,089-Ba. , 1968, British heart journal.

[11]  S. Stephen.  Unwanted effects of propranolol. , 1966, The American journal of cardiology.

[12]  P. Keelan,et al.  Multicenter trial of propranolol in angina pectoris. , 1966, The American journal of cardiology.

[13]  D. Chamberlain.  The Haemodynamic Effects of Beta-Adrenergic Blockade in Man , 1966 .

[14]  P. Gillam,et al.  Use of Propranolol in Angina Pectoris , 1965, British medical journal.

[15]  S. Bellet,et al.  Radioelectrocardiography during Exercise in Patients with Angina Pectoris: Comparison with the Postexercise Electrocardiogram , 1962, Circulation.

[16]  J. Riseman,et al.  Nitroglycerin and Other Nitrites in the Treatment of Angina Pectoris: Comparison of Six Preparations and Four Routes of Administration , 1958, Circulation.

[17]  B. Basil,et al.  Stability of H. pertussis Vaccine Estimated by Mouse-protection Test , 1957, British medical journal.

[18]  C. Robert.  DRUGS AND ANGINAL SYNDROME , 1955 .

[19]  L. Katz.  Mechanism of pain production in angina pectoris , 1935 .

[20]  D. Chamberlain,et al.  Angina Pectoris: A Method of Treadmill Assessment , 2007 .

[21]  W. Nayler,et al.  The negative inotropic effect of adrenergic betareceptor blocking drugs on human heart muscle. , 1969, Cardiovascular research.

[22]  W. S. Fowler,et al.  Maximal midexpiratory flow. , 1955, American review of tuberculosis.